Healthcare (XLV) vs Industrials (XLI)

Healthcare earnings come from drug volumes, hospital utilization, and managed-care premiums, which are largely inelastic to GDP. Industrial earnings come from aerospace orderbooks, freight volumes, mining and construction equipment cycles, and electrical infrastructure capex, all of which compress when growth slows. Historically the XLV/XLI ratio rises in the six to twelve months before US recessions and falls during the two-year recoveries that follow.

The April 2026 ratio of 0.863 sits inside its three-year range. The ratio bottomed near 0.79 in late 2024 (industrials leading on AI infrastructure capex) and peaked near 0.95 in mid-2022 during the recession scare. A move above 0.92 would indicate defensive rotation has arrived; a sustained move below 0.82 would indicate the cyclical phase is extending.

The 62 holdings in XLV concentrate heavily at the top. Eli Lilly at 13.80 percent reflects the GLP-1 obesity-drug franchise (Mounjaro and Zepbound) generating $40-plus billion in revenue and growing 50 percent year over year. Johnson and Johnson at 10.55 percent provides the diversified pharma-plus-medtech anchor after the Kenvue consumer-health spinoff. AbbVie at 6.74 percent reflects the post-Humira portfolio with Skyrizi and Rinvoq carrying volume growth. UnitedHealth at 6.10 percent and Merck at 5.40 percent round out the top five.

The top five represent approximately 42 percent of XLV. That concentration matters because Lilly alone now drives more daily XLV variance than any other single name. When Lilly disappoints on quarterly script trends or pipeline data, XLV falls hard despite the broader sector being stable.

XLI holds 82 stocks across aerospace and defense, machinery, transports, and electrical equipment. Caterpillar at 7.06 percent reflects mining and construction equipment exposure. The two GE successor companies combined sit at 11.13 percent (GE Vernova at 5.70 percent on grid and gas turbine demand, GE Aerospace at 5.43 percent on commercial-engine aftermarket). RTX at 4.55 percent and Boeing at 3.41 percent provide commercial-aerospace and defense leverage.

The top five represent approximately 26 percent of XLI, less concentrated than XLV. The breadth means XLI tracks underlying cyclical conditions more reliably than any single subsector. Aerospace orderbooks alone (Boeing plus Airbus combined backlog above 14,000 aircraft, eight to ten years at current build rates) provide multi-year visibility that smooths XLI earnings even during macro slowdowns.